Korro Bio (KRRO) Cash & Equivalents (2018 - 2026)

Korro Bio's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $61.7 million for Q1 2026.

• Quarterly Cash & Equivalents fell 3.81% year-over-year to $61.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.7 million (down 3.81% YoY) and the FY2025 annual result came in at $21.8 million, down 60.78% from the prior year.
• Cash & Equivalents was $61.7 million for Q1 2026 at Korro Bio, up from $21.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $166.2 million in Q4 2023 and bottomed at $21.8 million in Q4 2025.
• A 5-year average of $59.7 million and a median of $43.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 70.55% — and 2023, when it surged 357.3%.
• Korro Bio's Cash & Equivalents stood at $36.3 million in 2022, then jumped by 357.3% to $166.2 million in 2023, then tumbled by 66.51% to $55.6 million in 2024, then tumbled by 60.78% to $21.8 million in 2025, then jumped by 182.7% to $61.7 million in 2026.
• Business Quant data shows KRRO's Cash & Equivalents at $61.7 million in Q1 2026, $21.8 million in Q4 2025, and $24.2 million in Q3 2025.